Abstract Dolutegravir (DTG), elvitegravir (EVG) and raltegravir (RAL) 90/95 ] values in the low nanogram per millilitre range, and they retain antiviral activity against strains of HIV with acquired resistance to other classes of ARVs. Each of the INSTIs has unique pharmacokinetic/ pharmacodynamic properties, influencing its role in clinical use in specific subsets of patients. RAL and DTG have minimal drug-drug interaction profiles, as their metabolism has minimal cytochrome P450 (CYP) involvement. Conversely, EVG metabolism occurs primarily via CYP3A4 and requires pharmacokinetic boosting to achieve systemic exposures amenable to once-daily dosing. EVG and DTG have the added benefit of availability of fixed-dose combination tablets, allowing for convenient and simplified ARV regimens. RAL is the only INSTI to be listed as a preferred agent in the current US perinatal treatment guidelines. All three INSTIs are recommended regimens for treatment-naïve individuals in the US adult and adolescent HIV treatment guidelines. This review summarizes and compares the pharmacokinetics and pharmacodynamics of the INSTIs, and describes specific pharmacokinetic considerations for special patient conditions: hepatic impairment, renal dysfunction, pregnancy and coinfections.
Introduction
There are an estimated 36 million people living with human immunodeficiency virus (HIV) infection globally. With the advent of antiretroviral therapy (ART), HIV has become a chronic, manageable condition. However, in the absence of a sterilizing cure, ART is a lifelong commitment. Triple-drug combinations consisting of antiretrovirals (ARVs) targeting the virus in two steps in the viral life cycle are the current standard of care for ART [1] . An HIV integrase strand transfer inhibitor (INSTI) co-administered & Courtney V. Fletcher cfletcher@unmc.edu with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are part of five of the six recommended regimens for ART-naïve patients in the US Department of Health and Human Services adult and adolescent HIV treatment guidelines [1] . The INSTI class is the newest class of drugs that have become available to treat HIV, and it targets the HIV integrase enzyme, which incorporates pro-viral HIV-1 DNA into the host cell genome. The first clinically available INSTI, raltegravir (RAL), was approved in 2007, followed by the second-generation INSTIs elvitegravir (EVG) in 2012 and dolutegravir (DTG) in 2013. In addition to their role in therapy for ART-naïve patients, INSTIs retain potency against strains of HIV that are resistant to other classes of ARVs such as protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this manner, INSTIs offer novel treatment options for patients with both acquired and transmitted resistance to other ARV classes.
This review summarizes the clinical pharmacokinetics of the three INSTIs currently approved by the US Food and Drug Administration (FDA) for treatment of HIV in adult patients. Because selection of optimal ART for special patient populations may be complicated by changes in ARV pharmacokinetics, drug-drug interactions (DDIs) or overlapping adverse events, the available evidence for the impacts of hepatic impairment, renal dysfunction, pregnancy or co-infections on the pharmacokinetics of INSTIs is summarized. Finally, the pharmacodynamics of the INSTIs are compared.
Pharmacokinetics of INSTIs
The pharmacokinetic characteristics of INSTIs in healthy subjects and HIV-infected individuals are summarized in Table 1 . 
Dolutegravir
DTG is available as a 50 mg film-coated tablet and a fixeddose combination (FDC) tablet containing DTG 50 mg, abacavir (ABC) 600 mg and lamivudine (3TC) 300 mg. DTG may be given to adults as 50 mg once daily for patients without INSTI-associated resistance substitutions, or 50 mg twice daily for patients with known or suspected INSTI-associated resistance substitutions. Studies have described the pharmacokinetics of DTG (S/GSK1349572) in single-and multiple-dose strategies with doses ranging from 2 to 100 mg in healthy volunteers. DTG was readily absorbed with a median maximum concentration (C max ) achieved between 0.5 and 1.25 h post-dose in healthy volunteers; similar studies in HIVinfected persons found that C max occurred within 2.5 h [2, 3] . Low-, moderate-and high-fat meals increased DTG area under the concentration-time curve (AUC) values by 33, 41 and 66 %, respectively, although current manufacturer prescribing information indicates that DTG may be taken without regard to meals [4, 5] . Like that of other INSTIs, DTG absorption is impaired by co-administration with divalent or trivalent cations, which may be overcome by dose separation. Once absorbed, DTG binds extensively ([99 %) to the plasma proteins albumin and alpha-1-acid glycoprotein [3, 6] . Bioequivalence of an FDC tablet compared with single-tablet DTG 50 mg and combination ABC/3TC 600/300 mg has been demonstrated [7] .
DTG exhibits bi-exponential elimination with a elimination half-life (t ) ranging from 13 to 15 h in healthy volunteers, while t of 11-12 h has been reported in HIV-infected individuals [2, 3] . DTG exposure, as measured by AUC, was dose proportional from 2 to 100 mg, while C max was slightly less than dose proportional in single-dose, healthy volunteer studies [3] . Repeated-dose studies found that AUC during a dosage interval (AUC s ) and the concentration at the end of the dosing interval (C trough ) increased proportionally with doses in the 10-50 mg range, while C max increased slightly less than proportionally. Steady state was reached within 5 days of daily dosing in healthy volunteer, multiple-dose studies. AUC, C max and C trough accumulation ratios ranged from 1.24 to 1.42, from 1.16 to 1.36 and from 1.29 to 1.53, respectively, within the doses that were evaluated [3] . Similar accumulation ratios (1.23-1.43) were observed in studies of HIV-infected individuals [2] . After DTG 50 mg orally daily, the mean steady-state DTG C trough values were *25-fold higher than the protein binding-adjusted concentration inhibiting viral replication by 90 % (IC 90 ) values in healthy volunteers [3] .
In vitro, DTG has been found to be a substrate for the efflux transporters P-glycoprotein (P-gp) and human breast cancer resistance protein (BCRP). In human hepatocytes, uridine diphosphate (UDP)-glucuronosyltransferase (UGT) 1A1 was the primary enzyme responsible for DTG metabolism, while cytochrome P450 (CYP) 3A4 was a minor metabolizing pathway along with minimal contributions from UGT1A3 and UGT1A9. DTG is a substrate for UGT and CYP enzymes but does not appear to significantly induce or inhibit these enzymes. DTG also does not inhibit multidrug resistance-associated protein (MRP) 2, organic anion transporting polypeptide (OATP) 1B1/3, organic cation transporter (OCT) 1 or the following CYPs: 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 3A4 or 2B7. Notably, DTG inhibits OCT2 (IC 50 1.9 lM), which provides a basis for the mild increases in serum creatinine seen in clinical use of DTG in the treatment of HIV infection. Collectively, the in vitro data demonstrate DTG's low potential for clinically meaningful DDIs [8] .
In vivo metabolism and excretion of DTG was studied in a mass balance study of healthy male volunteers. After a 20 mg oral dose of DTG, 95.6 % of the dose was recovered in faeces (64 %) and urine (31.6 %). Unchanged DTG was the primary circulating entity in blood plasma, while an inactive glucuronide (18.9 %) formed via UGT1A1 was the principal metabolite recovered in urine. Minor metabolic pathways were identified via oxidation by CYP3A4 (7.9 %), as well as oxidative deflourination and glutathione substitution (1.8 %) [9] .
Population pharmacokinetic analysis in treatment-naïve, HIV-infected persons was performed by combining data from three studies: a proof-of-concept study (study no. ING111521) [2] , a phase 2b study (SPRING-1; study no. ING112276; ClinicalTrials.gov study ID NCT00951015) [10] and a phase 3 study (SPRING-2; ClinicalTrials.gov study ID NCT01227824) [11] . Population parameter estimates, derived from data on 3357 plasma samples from 563 subjects, were apparent oral clearance (CL/F) 0.901 L/h, apparent volume of distribution (V d /F) 17.41 L, absorption rate constant 2.24 h -1 and absorption lag time 0.263 h. Weight, smoking status, age and total bilirubin were predictors of CL/F, although none of these covariates were found to be clinically significant. Race and ethnicity, hepatitis B and C virus (HBV and HCV) co-infection, creatinine clearance (CL CR ), albumin, alanine aminotransferase and aspartate aminotransferase did not impact the pharmacokinetics of DTG within the studied population [12] .
DTG benefits from having relatively low pharmacokinetic variability in comparison with other INSTIs. In a phase 2a study investigating DTG pharmacokinetics in HIV-infected individuals, variability was found to be low, with coefficients of variation (CVs) in the 25-50 % range for C max , C trough and AUC s [2, 3] .
Elvitegravir
EVG (GS9137) is available in two FDC tablets, each given once daily in adults and containing EVG 150 mg, the pharmacokinetic enhancer cobicistat (COBI) and emtricitabine (FTC). One product includes tenofovir disoproxil fumarate (TDF), while the other includes tenofovir alafenamide (TAF). Additionally, EVG 85 mg is available for use once daily in individuals receiving ritonavir (RTV)-boosted, PI-based ART. The manufacturer recommends that all formulations be taken with a meal [13] [14] [15] .
In single-dose studies of unboosted EVG at doses of 100, 200, 400 and 800 mg given orally to healthy individuals, mean (CV) C max values of 108 (55 %), 160 (19 %), 264 (30 %) and 455 (33 %) ng/mL were reported with each respective dose. The time to reach C max (t max ) was 1.3-2.5 h post-dose, and AUC from time zero extrapolated to infinity (AUC ? ) was found to be less than dose proportional [16] .
During the clinical development of EVG, it was recognized that co-administration of RTV, a potent CYP3A4 inhibitor used for pharmacokinetic boosting of PIs, resulted in substantially higher EVG exposures. AUC s values for EVG were *20-fold higher when it was given with RTV 100 mg than for EVG alone [17] . COBI (GS-9350), a novel, potent and selective CYP3A4 inhibitor, was subsequently studied for its ability to enhance EVG pharmacokinetics. COBI has advantages as an ARV pharmacokinetic enhancer because it inherently lacks any activity against HIV-1 and is better tolerated than RTV. The relative bioavailability of EVG boosted with COBI (EVG/COBI) was compared with EVG boosted with RTV 100 mg (EVG/RTV) in a study of healthy human subjects. Relative to EVG/RTV, the geometric least-squares mean ratios (90 % confidence intervals [CIs]) for AUC s , C max and C trough of EVG were 118 (110-126), 108 (100-116) and 110 (95.3-127), respectively, when EVG 150 mg was combined with COBI 150 mg [18] . Because EVG efficacy is closely linked with C trough values, a higher COBI dose of 150 mg was subsequently investigated. With the higher dose of COBI, the EVG AUC s values were bioequivalent to EVG/RTV exposures, while both C max and C trough were significantly higher than those observed with EVG/RTV. The median (quartile 1, quartile 3) t of EVG (with COBI) was 9.15 h (7.70, 12.4) compared with 3 h when EVG was given alone [18, 19] . Collectively, these studies provided evidence for once-daily dosing of EVG when it is given with COBI 150 mg. The available EVG FDC products are both formulated with COBI 150 mg [14, 15] .
The oral bioavailability of EVG is significantly enhanced when it is given with a meal. A food interaction study of EVG, given as EVG/COBI/FTC/TDF, found that the mean AUC ? and C max increased by 34 and 24 %, respectively, after dosing with food [20] . Follow-up studies in healthy Japanese males confirmed these findings, showing decreases in AUC ? of up to 50 % when EVG was taken on an empty stomach as compared with either a standard breakfast or a protein-rich breakfast [21] .
When EVG is given orally with food, C max is reached in approximately 4-4.5 h. Although EVG absorption is not changed with alterations in stomach pH, absorption is significantly decreased by co-administration with divalent and trivalent cations, such as those found in multivitamins and antacids, which may be overcome by separating the dosing times of the two products [22, 23] . EVG absorption does not appear to be significantly altered with changes in intestinal P-gp expression. Ex vivo experiments have demonstrated that EVG is highly ([99 %) bound to the plasma proteins albumin and alpha-1 acid glycoprotein, with a preference for the former.
EVG's metabolism occurs primarily via CYP3A4 in the liver and intestine. Additional metabolism of EVG occurs via UGT1A1 and 1A3 to primary and secondary glucuronidated metabolites. The primary metabolites of EVG have substantially reduced activity against HIV-1 and do not play a major role in EVG efficacy [24] . Mass balance studies in healthy human subjects after a radiolabelled dose of EVG 50 mg plus RTV 100 mg demonstrated that *95 % of the oral dose was recovered in faeces, while *6.7 % of the dose was recovered in urine. Untransformed EVG was the primary circulating entity in plasma, accounting for *93 % of the circulating radioactivity.
Raltegravir
RAL (MK-0518) is available in three formulations: a 400 mg film-coated tablet, 25 and 50 mg chewable tablets, and 100 mg granules for suspension [25] . For adults, the dose of RAL is 400 mg twice daily, with or without food.
RAL pharmacokinetics are distinguished within the INSTI class as having markedly high inter-and intrapatient variability. CVs [200 % have been observed from repeated plasma concentration measurements within individual patients receiving stable RAL-containing ART [26] . RAL is rapidly absorbed, with a t max of approximately 3 h. Once absorbed, RAL is approximately 76-83 % protein bound, mainly to albumin and not to alpha-1-acid glycoprotein [25, 27] . Secondary plasma concentration-time peaks often occur with RAL, indicative of either enterohepatic recirculation or, possibly, delayed oral absorption. Like those of the other INSTIs, RAL pharmacokinetics are altered when it is given with divalent and trivalent cations, which may be overcome by dose separation [28] . The absolute bioavailability of RAL has not been established, because of the lack of a parenteral formulation; however, HIV-infected individuals have 25-30 % reduced bioavailability relative to healthy subjects [29] . Food appears to increase the amount of variability in the pharmacokinetics of RAL, although the mechanism is not completely clear. Studies of fasted and fed effects on RAL pharmacokinetics have revealed significant changes in AUC. In comparison with a low-fat meal, a 46 % decrease in AUC was observed when RAL was given in the fasted state. However, after moderate-or high-fat meals, AUC values were increased by 13-212 % [30] . Although substantial effects on pharmacokinetics have been noted with meals, no significant differences in efficacy have been noted when RAL is given with or without food [25] .
In healthy human subjects, the RAL t max was 1-2 h post-dose at steady state. The t was 7-12 h after multiple doses of 100-800 mg twice daily. Steady state is reached in approximately 2 days of twice-daily dosing, and little accumulation occurs. C max is slightly less than dose proportional, with observed geometric means (GMs) of 4.97 and 8.77 lg/mL after multiple 400 and 800 mg doses, respectively. The mean renal clearance of RAL in an adult male receiving 400 mg twice daily at steady state is 3.63 L/h. AUC ? values were found to be similar in adult male and female subjects [31] , which is in contrast to combined data from HIV-infected individuals and healthy human subjects, where 65 % higher RAL exposures were observed in females than in males [29] .
In a study of ART-naïve, HIV-infected adults given 10 days of twice-daily RAL doses of 100, 200, 400 or 600 mg, C trough values increased with higher doses, while C max values increased up to the 400 mg dose; the 600 mg dose had a slightly lower C max than the 400 mg dose (with GMs of 2.0 vs 1.69 lg/mL) [32] . Because of the high pharmacokinetic variability noted in this study, the RAL t could not be estimated. The authors did note that the elimination profiles of RAL in this patient population appeared to mimic those seen in healthy volunteer studies, where elimination occurred in a bi-exponential fashion, with an initial t of approximately 1 h and a terminal t of 7-12 h [31] [32] [33] .
A mass balance study performed in healthy human subjects after a single radiolabelled RAL dose of 200 mg indicated that 51 % of the dose was recovered in faeces, while 32 % was recovered in urine [34] . Both parent RAL and a glucuronide metabolite of RAL (M2) were present in the urine and represented 9 and 23 % of the total RAL dose that was given. RAL was the only form of the dose recovered in faeces, although it is believed that RAL recovered from faeces includes glucuronidated RAL, further hydrolysed in bile before elimination. The major circulating entity in blood plasma was RAL, which represented 70 % of the total radioactivity. The remaining radioactivity could be attributed to RAL glucuronide metabolites. Mechanistic studies indicate that UGT1A1 is the major metabolic enzyme responsible for clearance of RAL in humans, with minor contributions from UGT1A3 and UGT1A9. Genetic polymorphisms in UGT1A1, such as 28/28, result in slower clearance of RAL and associated higher plasma concentrations (*41 % higher); however, this increase is not considered clinically significant [35] .
The pharmacokinetics of RAL 800 mg once daily were investigated in HIV-infected, treatment-naïve individuals. AUC s values were similar when RAL was given as 800 mg daily compared with 400 mg twice daily [GM ratio (90 % CI) 1.17 (0.8-1.72)]. However, C max values were *4-fold higher [3.98 (2.58-6.16)] and C trough values were *6-fold lower [0.15 (0.09-0.26)] with the daily dose. Once-daily dosing of RAL was ultimately found to be virologically inferior to twice-daily dosing (see Sect. 4.3 for further discussion) [25, 36, 37] .
Pharmacokinetics in Special Populations

Hepatic Impairment
Liver disease may influence ARV pharmacokinetics because of changes in liver blood flow or shunting, altered synthesis of plasma proteins, metabolism via CYP enzymes and, to a lesser extent, glucuronidation [38] [39] [40] . The FDA has issued a formal guidance for evaluating the effect of hepatic impairment on drug pharmacokinetics [41] . Product labelling for all INSTIs recommends no dose adjustment for patients with mild to moderate hepatic impairment (Child-Pugh class A or B), but none of the labels recommends their use in, or gives dosing information for, patients with severe hepatic impairment (Child-Pugh class C) [4, [13] [14] [15] 25] . Unless indicated otherwise, moderate hepatic impairment was defined as a Child-Pugh score of 7-9 in all studies described in this section. Table 2 summarizes comparative studies of INSTI pharmacokinetics in patients with hepatic impairment.
Dolutegravir
The phase 2/3 efficacy trials of DTG included 71 patients with HIV/HCV and 27 patients with HIV/HBV co-infection without cirrhosis. Population pharmacokinetics in the HCV co-infected patients indicated no clinically relevant effect on DTG pharmacokinetics, but the evaluation in HIV/HBV co-infected patients was limited by the sample size [12, 42] . One study evaluated DTG in HIV-seronegative participants with moderate hepatic impairment in comparison with healthy participants [43] . After a single dose of DTG 50 mg, no difference was observed in pharmacokinetic parameters for total DTG concentrations. Unbound DTG concentrations were 48-106 % higher in participants with hepatic impairment than in healthy participants at two time points post-dose. Higher unbound fractions were correlated with a higher Child-Pugh score, lower albumin concentrations and increased bilirubin concentrations (all P \ 0.001).
Elvitegravir
Population pharmacokinetic evaluations from phase 2/3 efficacy trials in HIV-infected patients with HBV or HCV co-infection identified no impact of co-infection without 
Raltegravir
The pharmacokinetics of RAL 400 mg after a single dose was evaluated in HIV-seronegative volunteers with or without moderate hepatic insufficiency [46] . No clinically significant differences were observed in any of the RAL pharmacokinetic parameters. In another study in HIV-infected patients, no difference in RAL C trough was observed in HIV/HCV co-infected persons without cirrhosis compared with HIV mono-infected persons after 4 weeks of RAL 400 mg twice daily [47] .
Unique to RAL, published data describe RAL exposure in HIV/HCV co-infected individuals with cirrhosis. HIV/HCV co-infected patients with and without advanced cirrhosis received RAL 400 mg twice daily for 5 days in combination with their existing PIbased ART regimen [48] . Patients with advanced cirrhosis had 72 % higher total RAL exposure and notably higher C trough values. The authors reported no adverse events or RAL treatment discontinuation during the study period.
RAL pharmacokinetics have also been evaluated in HIV-infected persons with end-stage liver disease (ESLD) and in patients post-liver transplantation [49] . Ten HIVinfected individuals who had ESLD (with a Model for End-Stage Liver Disease [MELD] score C15) were switched from effective ART (HIV RNA \50 copies/mL) to RAL-based ART. After 1 month on therapy, total RAL exposure was higher in patients with ESLD (with a median AUC during a 9-h interval [AUC 9 ] of 33.5 lg h/ mL) than in historical controls with normal hepatic function. In these ten persons, RAL was well tolerated, and all participants remained virologically suppressed on ART. Consistent with RAL pharmacokinetics in other populations, high variability was observed in total and unbound RAL concentrations (with AUC 9 interpatient CVs of 95 and 91 %, respectively). The same study reported RAL pharmacokinetics in five HIV-infected persons who underwent liver transplantation and initiated RAL-based ART postoperatively. After 1 month, the total and unbound RAL exposures were similar to those observed in persons with ESLD.
Renal Impairment
Because none of the INSTIs is primarily eliminated by renal excretion, a significant impact on INSTI exposure is not expected in persons with renal impairment. Because renal impairment can influence hepatic metabolism and drug transporters, a renal impairment study is required for chronically administered drugs [50] . Table 2 summarizes the comparative studies conducted in severe renal impairment. Unless indicated otherwise, severe renal impairment was defined as a CL CR \30 mL/min in all studies discussed in this section.
Dolutegravir
Unexpectedly, total plasma DTG exposure was 40 % lower following a single dose of DTG 50 mg in HIV-seronegative volunteers with severe renal impairment compared with matched controls [51] . Population pharmacokinetic modelling from the phase 3 clinical trial did not find an association between the degree of mild or moderate renal impairment and total DTG exposure, and the reason for lower DTG concentrations during severe renal insufficiency is unclear [42] . Given these results, paired with the pharmacodynamics of DTG (see Sect. 4.1 for further discussion), DTG may be given without dose adjustment in INSTI-naïve persons with mild, moderate or severe renal impairment. However, because of this observed decrease in DTG exposure, caution is warranted for those with severe renal impairment and known or suspected INSTI resistance mutations [4] . DTG has not been evaluated in persons receiving renal replacement therapy; however, because of its high protein binding ([99 %), it is not expected to be removed significantly [4, 51] .
Elvitegravir
The EVG/COBI/TDF/FTC co-formulated tablet is not recommended for initial therapy in persons with a CL CR B70 mL/min, because of an imbalance of patients who received EVG/COBI/TDF/FTC developing renal adverse events in trials of clinical efficacy (9 vs 3 persons receiving comparator regimens) [44] . In addition, because of the coformulation with TDF, EVG/COBI/TDF/FTC should be discontinued in persons whose CL CR falls below 50 mL/ min during therapy, as TDF requires a dose reduction at a CL CR below this threshold. Given these restrictions, there are no pharmacokinetic data available for this formulation in persons with any degree of renal insufficiency [44] .
EVG/COBI/TAF/FTC may be used for patients with moderate renal insufficiency (CL CR 30-69 mL/min). The safety and efficacy of EVG/COBI/TAF/FTC was evaluated in 242 patients with stable, moderate renal insufficiency (median CL CR 56 mL/min), and intensive pharmacokinetic sampling was conducted in 30 participants between weeks 4 and 8 [52] . EVG and COBI exposures (with AUC values of 27.1 and 9.92 lg h/mL, respectively) were similar to historical exposure data [44] and were comparable between persons with CL CR above or below 50 mL/min.
Minimal data are available for EVG co-administered with RTV. Data on file with the company indicate that no clinically relevant differences in EVG pharmacokinetics were observed in participants with severe renal impairment when EVG was boosted with RTV [13] . Removal of EVG by renal replacement therapy is expected to be low, because of high EVG protein binding (98-99 %).
Raltegravir
No differences in pharmacokinetic parameters were observed in one evaluation of single-dose RAL 400 mg in HIV-seronegative participants with severe renal insufficiency [46] . The extent of drug removal by renal replacement therapy is expected to be minimal because of high plasma protein binding, and this has been confirmed in case reports to date [53, 54] .
Pregnancy
As in non-pregnant adults, ART is recommended for all HIV-infected, pregnant women by the US perinatal HIV treatment guidelines [55] . In addition to the known efficacy, safety and tolerability of INSTIs in the treatment of non-pregnant adults, INSTIs may play an important role in managing HIV infection during late pregnancy because of the rapid viral decay observed with INSTI therapy. On the basis of accumulating clinical and pharmacokinetic data, RAL was included as a preferred option for ARV-naïve, pregnant women in the 2015 update of the US perinatal HIV guidelines [55] .
Physiological changes during pregnancy are known to impact the pharmacokinetics of some ARVs, resulting in dose adjustment recommendations for certain ARVs during pregnancy in order to maintain optimal pharmacokinetic exposure. Specific metabolic pathways that may influence INSTI metabolism include induction of UGT1A1 and CYP3A4 during pregnancy [56, 57] . Therefore, the guidelines recommend assessment of ARV pharmacokinetics during pregnancy prior to routine clinical use [55] . Published data on INSTI pharmacokinetics in pregnant women are summarized in Table 3 . In addition to maternal influences on ARV pharmacokinetics, fetal exposure to ARVs during the antepartum period is also important for prevention of HIV transmission. McCormack and Best [58] recently published a comprehensive review of ARV placental transfer; therefore, only in vivo information published since that recent review is described herein.
Dolutegravir
The perinatal treatment guidelines do not recommend, or make specific dosing recommendations for, DTG use in ARV-naïve, pregnant women [55] . Since the guidelines' last update, the first pharmacokinetic evaluation of DTG in 21 pregnant women has been presented [59] . DTG exposure was lower during pregnancy than postpartum in the same group of women. Although DTG pharmacokinetics were variable, the authors concluded that the postpartum pharmacokinetics were similar to historical values [4] , suggesting that the postpartum exposure represented an appropriate control group. In the same study, exposure to, and elimination of, DTG was assessed in ten infants over 5-9 days after delivery. The median concentration 6.9 h after delivery was 1.96 (interquartile range [IQR] 1.42-2.48) lg/mL, demonstrating significant maternal-tofetal transfer of DTG; t was 34.5 h, in contrast to 14 h reported in historical adult patients [4] .
Elvitegravir
No systematic evaluation of EVG pharmacokinetics during pregnancy is available; therefore, EVG is not recommended in the US treatment guidelines [55] . The first case report of EVG use during pregnancy was recently published, and the drug was administered as EVG/COBI/TDF/ FTC once daily [60] . The woman's AUC s values for EVG and COBI were measured at 34 weeks' gestational age and at 6 weeks postpartum. The EVG AUC s was similar during and after pregnancy (data not provided); however, the patient's AUC s postpartum was lower than historical values. C trough after observed drug intake was 60 % lower during pregnancy than postpartum and was below the study-defined target concentration of 0.13 lg/mL [61] . Exposure to COBI (AUC s ) was 44 % lower during pregnancy than postpartum, which was similar to historical values. At delivery, the EVG maternal and cord plasma concentrations of EVG were both 0.3 lg/mL; however, COBI was below the lower limit of quantification (LLQ; 0.03 lg/mL) in both samples.
Raltegravir
As in non-pregnant adults, RAL exhibits high pharmacokinetic variability during pregnancy when given either with or without food, as was observed in two studies of pregnant and postpartum women. In the first study, RAL was given on an empty stomach to 42 women during pregnancy [62] . RAL exposure (AUC s ) was approximately 50 % lower during both the second and third trimesters of pregnancy than postpartum. The authors selected a target C trough of 0.035 lg/mL based on the tenth percentile value in non-pregnant historical controls [25] ; 69, 80 and 79 % of participants had values above this C trough target during the second trimester, during the third trimester and postpartum, respectively, with notably high variability (\0.01-0.917 lg/mL).
More recently, RAL was given with a meal (650 kcal; 30 g fat) during the third trimester (median gestational age 33 weeks) and postpartum (median 5 weeks) in 22 women [63] . Overall, the RAL AUC s and C trough were 29 and 36 % lower during pregnancy than postpartum; significant variability was observed in all pharmacokinetic parameters. Three participants (13.6 %) failed to achieve virological suppression before delivery. Of those, one person's C trough during the third trimester was below the desired threshold established by the authors [0.020 lg/mL, based on the comparison between RAL 800 mg once daily and 400 mg twice daily [64] (see Sect. 4.3 for further discussion)]. No other patient's values fell below this threshold during or after pregnancy. Fetal exposure to RAL was evaluated in nine paired cord and maternal blood samples at delivery (median 10 h after the last RAL dose). The ratio of RAL in cord/maternal blood was 1.21 (IQR 1.02-2.17), similar to previously reported values [58] .
Given the available data, the high interpatient variability and the virological efficacy observed in these studies (92 % [62] and 86 % [63] virological suppression at delivery), the US treatment guidelines currently recommended RAL 400 mg twice daily without dose adjustment in ARVnaïve, pregnant women [55] . 
Co-infections
Pharmacokinetic evidence in both healthy volunteers and individuals co-infected with HIV and tuberculosis (TB) has shown substantial reductions in exposure of RAL when it is given in combination with rifampicin. Two studies identified approximately 40 % lower RAL AUCs when RAL was combined with rifampicin, presumably due to the UGT1A1 induction effect of rifampicin [35, 66] . Pharmacodynamic outcomes with the combination of RAL and rifampicin have also been studied. In individuals co-infected with HIV/TB, the ANRS 12 180 (REFLATE TB) study investigated the use of RAL-based ART in individuals receiving drug-sensitive TB treatment including rifampicin. In an analysis of 153 individuals randomized to receive either RAL 400 mg twice daily, RAL 800 mg twice daily or efavirenz (EFV) 600 mg once daily, all in combination with TDF/3TC, RAL 400 mg twice daily performed similarly to either dose-escalated RAL 800 mg twice daily or EFV-based regimens: the week 24 virological suppression rates were 76 % with RAL 400 mg, 78 % with RAL 800 mg and 63 % with EFV [65] . Studies investigating the use of INSTI-based ART in HIV and HCV co-infected individuals are lacking. DDI data in healthy volunteers suggest minimal effects of newer HCV direct-acting antivirals (DAAs) on RAL and DTG pharmacokinetics [1] ; however, the effects of both the disease state and HCV treatment on INSTI pharmacodynamics remain to be investigated. Pharmacokinetic and pharmacodynamic data are deficient for use of INSTIs in individuals co-infected with HIV and malaria. On the basis of known pathways of metabolism for INSTIs, DDIs between RAL and DTG are unlikely with antimalarial agents, while DDIs with EVG/ COBI or EVG/RTV may be expected. Table 4 provides a comparison of selected pharmacodynamic characteristics for the three INSTIs.
Pharmacodynamics of INSTIs
Dolutegravir
The pharmacodynamic characteristics of DTG have been evaluated through studies in which it was given as monotherapy or in combination with NRTIs to treatmentnaïve and treatment-experienced persons with and without documented resistance to RAL and EVG. DTG monotherapy in doses of 2, 10 and 50 mg once daily for 10 days was given to 35 INSTI-naïve, HIV-infected persons not receiving ART [67] . Monotherapy was associated with a reduction in plasma HIV RNA ranging from 1.5 log 10 with 2 mg to 2.03 log 10 with 10 mg and 2.46 log 10 with 50 mg. Seven of ten recipients of 50 mg once daily had plasma HIV RNA \50 copies/mL at day 11. Plasma HIV RNA reductions (log 10 changes) were best predicted by the DTG C trough following a maximum-effect (E max ) relationship. The estimated concentration producing a 50 % effect (reduction of HIV RNA) in vivo (EC 50 ) was 36 ng/mL; with a Hill factor of 1, a concentration of 324 ng/mL was associated with 90 % of E max . The GM C trough values observed with the three doses were 40 ng/mL with 2 mg, 190 ng/mL with 10 mg and 830 ng/mL with 50 mg. These data indicate that DTG monotherapy at 50 mg once daily produced concentrations well inside the plateau portion of the exposure-response relationship. A subsequent doseranging study evaluated DTG (10, 25 or 50 mg once daily) or EFV in combination with TDF/FTC or ABC/3TC in ARV-naïve persons [10] . At week 48, the proportions of participants who had HIV RNA \50 copies/mL were 91, 88 and 90 % in the DTG 10, 25 and 50 mg groups, respectively, and 82 % among those receiving EFV. The comparability of virological responses across the three different DTG doses suggests that additive to synergistic anti-HIV responses were achieved when DTG was combined with other ARVs. DTG 50 mg once daily was compared with twice-daily RAL in 822 treatment-naïve adults [11] . Both drugs were given with investigator-selected ABC/3TC or TDF/FTC. At the 48-week primary endpoint, 88 % of DTG recipients and 85 % of RAL recipients had HIV RNA \50 copies/ mL. At 96 weeks, 81 % of DTG recipients compared with 76 % of RAL recipients had HIV RNA \50 copies/mL. Virological non-response occurred in 5 % of those randomized to receive DTG and in 10 % of those randomized to receive RAL. In a similar design, once-daily DTG (50 mg) was compared with once-daily DRV/RTV, each given with investigator-selected ABC/3TC or TDF/FTC, in 484 ARV-naïve persons [68] . At the week 48 primary endpoint, 90 % of DTG recipients and 83 % of DRV/RTV recipients had HIV RNA \50 copies/mL. DTG was statistically superior (P = 0.025) to DRV/RTV. Drug-limiting adverse events were less frequent in DTG recipients; 2 % of DTG recipients and 4 % of DRV/RTV recipients discontinued therapy because of adverse events. The safety and efficacy of DTG and RAL were compared in INSTI-naïve but ARV-experienced persons with at least two-class resistance [69] . A total of 715 persons were enrolled; 354 received DTG and 361 received RAL. At week 48, 71 % of DTG recipients versus 64 % of RAL recipients had plasma HIV RNA \50 copies/mL (P = 0.03). Additionally, significantly fewer DTG recipients had virological failure with treatment-emergent INSTI resistance (4 vs 17, P = 0.003). In this study, the GM DTG C trough across 335 subjects was 850 ng/mL [42] . Those who had a DTG C trough in the lowest quartile (median 260 ng/ mL) had the lowest virological response rates (HIV RNA \50 copies/mL at week 24): 76 % in the lowest quartile versus 81-87 % across the second through fourth quartiles. Subjects with a DTG C trough in the lowest quartile were more likely to have concentrations below the LLQ, likely reflecting poor adherence and/or use of CYP3A inducers; the median DTG C trough in the lowest quartile was consistent with a 10 mg once-daily dose.
DTG pharmacokinetics were shown to be less than dose proportional in healthy human volunteers when the dose was increased from 50 to 100 mg daily. For this reason, a DTG dose of 50 mg twice daily was investigated in an attempt to increase DTG exposures in patients with prior INSTI resistance [70] . In this study, 183 treatment-experienced persons with documented resistance to RAL and EVG were enrolled in a functional 7-day monotherapy phase followed by a second phase with an optimized ARV background [70] . At week 24, 69 % of subjects had plasma HIV RNA \50 copies/mL. The overall GM DTG C trough was 2330 ng/mL and was similar in individuals who achieved HIV RNA \50 copies/mL and in those who did not (2420 vs 2120 ng/mL). A clear relationship was observed between the DTG inhibitory quotient (IQ; the ratio of the DTG C trough to baseline susceptibility of the virus to DTG, or IC 50 ) and the percentage of subjects at week 24 with HIV RNA \50 copies/mL [42] . However, this relationship was strongly driven by differences in IC 50 values, which ranged from 5110 ng/mL in the first quartile to 710 lg/mL in the fourth quartile, while DTG C trough values ranged from 1840 to 3860 ng/mL in the first to fourth quartiles [42] .
Elvitegravir
Forty ARV-naïve and ARV-experienced persons who were HIV infected but not currently on therapy received varying doses of EVG with and without RTV as monotherapy to evaluate pharmacokinetics and pharmacodynamics [71] . Concentrations of EVG were highest when it was combined with RTV. EVG C trough values were strongly associated with the anti-HIV effect (log 10 change in plasma HIV RNA), where E max was a 2.32 log 10 reduction in HIV RNA, EC 50 was 14 ng/mL and EC 90 was 126 ng/mL. Subsequently, 278 HIV-infected persons with HIV RNA C1000 copies/mL and C1 PI resistance mutation were randomized to receive EVG or a comparator RTV-boosted PI [72] . Three different doses of EVG, all given once daily with 100 mg of RTV, were evaluated: 20, 50 and 125 mg. The 20 mg EVG treatment arm was stopped at week 8 by the data safety monitoring board because that arm had a higher rate of virological failure. For the primary endpoint (a change in HIV RNA from baseline to week 24), the two remaining EVG arms (50 and 125 mg) were non-inferior to the comparator PI treatment arm, with 1.44 and 1.66 log 10 reductions in HIV RNA versus a 1.19 log 10 reduction in HIV RNA. The mean EVG C trough values in the three treatment arms were 67 ng/mL with 20 mg, 211 ng/mL with 50 mg and 263 ng/mL with 125 mg [44] . C trough with the 20 mg EVG dose was less than the protein binding adjusted IC 95 of 45 ng/mL, providing a reason why this dose was subtherapeutic and a rationale to maintain concentrations above this threshold. The EVG 125 mg with RTV 100 mg treatment arm achieved a statistically greater decrease in HIV RNA at week 24 than the PI arm, and this finding formed the basis for selection of this dose (and the level of systemic exposure) for evaluation in phase 3 studies.
Two phase 3, randomized, double-blind trials compared the efficacy of EVG with EFV or ATV/RTV, all given with TDF/FTC [61, 73] . EVG 150 mg was given once daily with COBI 150 mg. This dose combination (in an FDC with TDF and FTC) was shown to achieve concentrations similar to those seen with EVG 125 mg plus RTV 100 mg. Combined, these two studies enrolled 1408 treatment-naïve adults. In both studies, for the primary outcome of the proportion of subjects with HIV RNA \50 copies/mL, EVG/COBI was non-inferior to EFV (87.6 vs 84.1 %) and to ATV/RTV (89.5 vs 86.8 %). Pharmacodynamic relationships were investigated in an analysis performed by the FDA, where patients were separated into deciles according to the EVG C trough , and the percentages of subjects with HIV RNA \50 copies/mL were compared [44] . The median C trough in the lowest decile was 156 ng/mL, and the virological success rate was 87 %. The virological success rates in deciles with higher trough concentrations (234-916 ng/mL) ranged between 84 and 97 %. This analysis indicated that virological success was flat across the range of EVG trough concentrations achieved with the 150 mg dose. A trend towards different rates of virological success was observed in participants with baseline viral loads \100,000 copies/mL (92 %) in comparison with those who had loads [500,000 copies/mL (79 %). Collectively, these phase 3 trials confirmed the efficacy of the 150 mg once-daily dose of EVG/COBI predicted by the exposureresponse relationship.
Raltegravir
RAL is known to exhibit extremely high intra-and interpatient variability in plasma concentrations. For example, C trough values in participants taking 400 mg twice daily ranged from 5.3 to 4067 ng/mL [74, 75] . This variability has clouded the ability to elucidate clear concentrationeffect relationships. A 10-day monotherapy trial in ARVnaïve persons is illustrative. Twenty-eight individuals received RAL doses of 100, 200, 400 and 600 mg twice daily for 10 days [76] . The median AUC values were 2.3, 5.0, 8.2 and 7.2 lg h/mL with the 100, 200, 400 and 600 mg doses, respectively; the median C trough values were 22, 65, 72 and 90 ng/mL, respectively. The ranges for C trough with the 400 mg twice-daily dose were 29-118 ng/ mL, completely encompassing the median C trough range across the dose range of 100-600 mg twice daily. This interpatient variability in pharmacokinetic concentrations contributes to variability in virological responses. In a phase 3, randomized, dose-ranging study of 200, 400 and 600 mg of RAL twice daily, with an optimized background regimen in treatment-experienced persons, the proportions of participants with HIV RNA \50 copies/mL at week 24 were 63, 48 and 56 %, respectively [77] . These data illustrate that high interpatient pharmacokinetic variability, which contributes to the lack of dose proportionality and overlapping concentrations across a range of doses, obscures quantitative understanding of the concentrationresponse relationship. The flatness of the response relationship was also observed in a large, pivotal, placebocontrolled, phase 3 trial of RAL with optimized background therapy in persons in whom ART had failed, with triple-class drug resistance [75] . An exposure-response analysis conducted by the FDA found that virological success (HIV RNA \400 copies/mL) was similar (77 %) in patients with the lower median C trough of 33 ng/mL and the higher median C trough of 483 ng/mL [74] .
The existence of an exposure-response relationship for RAL was clearly shown in a trial comparing once-daily and twice-daily RAL dosing, in which 775 ARV-naïve persons were randomized to receive RAL 800 mg once daily or 400 mg twice daily, both with TDF/FTC [36] . A significantly lower proportion of participants who received RAL once daily had HIV RNA \50 copies/mL at week 48 than did those who received 400 mg twice daily (83 vs 89 %). An exposure-response analysis found that trough RAL concentrations with once-daily dosing correlated with virological response [64] . The GM RAL C trough values were 37 ng/mL with once-daily dosing compared with 169 ng/mL with twice-daily dosing. A greater proportion of participants who received once-daily dosing had trough concentrations below 14 ng/mL (the protein binding-adjusted IC 95 ): 42 vs 14 %. Participants who had RAL trough concentrations in the lowest quartile (median C trough 12.5 ng/mL) had a clear fall-off in virological response, with \80 % achieving HIV RNA \50 copies/mL. These data clearly indicate that an underlying exposure-response relationship exists for RAL, and they provide strong evidence that trough concentrations should be above the protein binding-adjusted IC 95 to achieve an optimal response. Additionally, they are illustrative that the shape of the concentration curve (from C max to the minimum concentration [C min ]) can affect pharmacodynamics.
Interpretations and Conclusions
The most distinguishing pharmacokinetic characteristic of the INSTIs is the difference in hepatic metabolism: EVG is primarily metabolized by CYP3A4, while DTG and RAL are primarily metabolized by UGT1A1. EVG must be given with a pharmacokinetic enhancer (booster), usually COBI because of the availability of co-formulations. As such, EVG/COBI has a higher likelihood of being a perpetrator of DDIs. The extensive clinical pharmacokinetic data derived from using RTV as a pharmacokinetic enhancer with PIs, however, largely applies to management strategies for COBI. DTG (in ARV-naïve persons) and EVG/COBI are administered once daily, while RAL requires twice-daily dosing. RAL is also distinguished by substantially higher degrees of intra-and interpatient pharmacokinetic variability. For all three INSTIs, there are differences in pharmacokinetic characteristics between healthy volunteers and HIV-infected individuals, and these illustrate the importance of developing clinical pharmacokinetic and pharmacodynamic data in the intended population, as discussed elsewhere [78] . Given the longer duration of clinical use of RAL, there is more evidence supporting standard dosing of RAL in patients with hepatic impairment (moderate through advanced cirrhosis), in patients with severe renal impairment and during pregnancy. DTG and EVG may be used at standard doses in patients with moderate hepatic impairment. In patients with severe renal dysfunction, standard-dose DTG is recommended for patients without INSTI resistance; however, DTG is not recommended for patients with INSTI resistance, because of unexpectedly lower concentrations in patients with severe renal dysfunction. EVG/COBI is not recommended for patients with severe renal dysfunction, but EVG/RTV may be used without dose adjustment. Additional data are required before DTG or EVG can be recommended for use in pregnant women.
In 50/90 ). IQ is the ratio of the drug concentration in any biological fluid (e.g. plasma, cerebrospinal fluid) divided by the in vitro inhibitory concentration, thus integrating in vivo pharmacokinetics and in vitro pharmacodynamics (i.e. how much drug you have, and how much drug you need) [79] . As discussed by the FDA, IQ is considered important in ARV drug development because a high IQ indicates that sufficient drug can be achieved, which may minimize the emergence of viral resistance, and this can inform selection of doses for phase 3 and 4 studies, as well as for different patient populations [80] . At approved doses, the hierarchy of IQs is DTG [ EVG [ RAL, and there are supporting correlations from clinical trials. DTG has been shown to be non-inferior to RAL in ARV-naïve persons and superior to RAL in ARVexperienced but INSTI-naïve persons [11, 69] . These findings are consistent with DTG having a higher IQ than RAL (17 vs 8) . For EVG, a dose of 20 mg once daily (with RTV) was inferior to doses of 50 and 125 mg [72] . IQ of a 20 mg dose would be approximately 1.5, compared with an IQ of 10 for the 150 mg dose. Once-daily RAL dosing of 800 mg has been shown to be inferior to 400 mg twice daily [36] . IQ for the once-daily regimen (C trough divided by IC 95 ) would be 2.5 compared with a value of 8 for the twice-daily regimen.
In clinical studies in ARV-naïve persons, at 48-week endpoints, RAL and EVG demonstrated non-inferiority compared with EFV: 86.1 % of RAL recipients versus 81.9 % of EFV recipients achieved HIV RNA \50 copies/ mL; 87.6 % of EVG recipients versus 84.1 % of EFV recipients achieved HIV RNA \50 copies/mL [73, 81] . DTG was shown to be statistically superior to EFV in ARV-naïve subjects at 48 weeks: 88 % of DTG recipients compared with 81 % of EFV recipients had HIV RNA \50 copies/mL [82] . DTG was also shown to be statistically superior to DRV/RTV in ARV-naïve subjects at 48 weeks, and in the only head-to-head trial of two INSTIs in ARV-naïve persons, DTG was non-inferior to RAL (88 % of DTG recipients compared with 85 % of RAL recipients had HIV RNA \50 copies/mL at 48 weeks) [68, 83] .
Current treatment guidelines in the USA recommend INSTI-based regimens as being among those preferred for ARV-naïve individuals [1] . There is evidence that the use of INSTIs has improved viral suppression rates in the USA. A study of 31,055 persons living with HIV and receiving care at eight clinical sites across the USA examined rates of viral suppression from 1997 to 2015 [84] . The percentage of these individuals with undetectable viral loads increased from 30 % in 1997 to 87 % in 2014. In multivariable analyses of participants receiving ART after 2010, older age, white race, male sex, better adherence and INSTI use were associated with an undetectable viral load. These findings are concordant with the clinical pharmacokinetic and pharmacodynamic profiles of these agents: convenient dosing, availability in co-formulations with other ARVs, high IQs conferring high potency and rapid drops in viral load, safety and good tolerability.
